The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review-Reference-Cited by-同舟云学术

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review

Published:2022-10 Issue:10 Volume:10 Page:e1423-e1442
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Stolbrink Marie,Thomson Helen,Hadfield Ruth M,Ozoh Obianuju B,Nantanda Rebecca,Jayasooriya Shamanthi,Allwood Brian,Halpin David M G,Salvi Sundeep,de Oca Maria Montes,Mortimer Kevin,Rylance Sarah

Funder

Wellcome Trust

World Health Organization

Publisher

Elsevier BV

Subject

General Medicine

Reference56 articles.

1. Priority actions for the non-communicable disease crisis;Beaglehole;Lancet,2011

2. Improving lung health in low-income and middle-income countries: from challenges to solutions;Meghji;Lancet,2021

3. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study;Asher;Lancet,2021

4. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries;Halpin;Int J Tuberc Lung Dis,2019

5. Global Action Plan for the prevention and control of noncommunicable diseases 2013–2020,2013

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries;Expert Review of Respiratory Medicine;2024-09-13

2. Olfactory Diagnosis Model for Lung Health Evaluation Based on Pyramid Pooling and SHAP-Based Dual Encoders;ACS Sensors;2024-09-09

3. Awareness of COPD in low-and middle-income countries and implications for treatment;Expert Review of Respiratory Medicine;2024-09-09

4. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs);Research in Social and Administrative Pharmacy;2024-09

5. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST);Advances in Therapy;2024-08-31